Newstral
Article
bizjournals.com on 2015-08-03 18:08
CSL completes $275M buy of Novartis influenza vaccine business
Related news
- CSL shares hit $100 but influenza vaccines may hurt earnings growthSydney Morning Herald
- CSL completes Novartis flu vaccine dealSydney Morning Herald
- GSK completes transaction with Novartisabc3340.com
- INovartis in advanced talks to buy Cytokineticsinvezz.com
- CSL makes mammoth play with $17.2 billion buySydney Morning Herald
- Buy CSL and Lendlease and dump miners for 2016Sydney Morning Herald
- Cerner completes $1.3 billion buy of Siemenskansascity.com
- Novartis to buy multiple sclerosis drug from GlaxoThe Globe and Mail
- MNovartis to buy Cadent for up to $770 millionmarketwatch.com
- FGSK to invest £275m in UKft.com
- Anheuser-Busch completes deal to buy SABMiller for $106 billionkansascity.com
- Novartis has assets to sell, investors wary of what it might buyReuters
- PERA posts $275m lossperthnow.com.au
- GSK to be No. 1 vaccine producer when it completes $25B asset swap with Novartis next weekbizjournals.com
- LVaccines & Vaccination Market 2021 High Growth Forecast due to Rising Demand and Future Trends | Key Companies: Abbott, AstraZeneca, Bavarian Nordic, Novartis, Bharat Biotech, Bio-Med, CSL, Emergen…liverpoolstudentmedia.com
- LGlobal Vaccines & Vaccination Market 2021 Financial Insights, Business Growth Strategies, Trends | Market Players: Abbott, AstraZeneca, Bavarian Nordic, Novartis, Bharat Biotech, Bio-Med, CSL, Emer…liverpoolstudentmedia.com
- Will CSL break the $100 barrier?Sydney Morning Herald
- Novartis said to hold talks to buy generics maker Amneal - Mon, 14 Nov 2016 PSTThe Spokesman-Review
- IIs Eli Lilly or Novartis the better buy after Q3 results?invezz.com
- Mount Sinai Medical Center completes $275M expansion (Photos)bizjournals.com